

The spectrum of psychiatric manifestations in subacute sclerosing panencephalitis: a systematic review of published case reports and case series

Ravindra Kumar Garg

*Sujita Kumar Kar

Hardeep Singh Malhotra

Shweta Pandey

**Amita Jain

Imran Rizvi

Ravi Uniyal

Neeraj Kumar

Department of Neurology

King George's Medical University

Lucknow, India: 226003

*Department of Psychiatry

King George's Medical University

Lucknow, India: 226003

**Department of Microbiology

King George's Medical University

Lucknow, India: 226003

Correspondence

Ravindra Kumar Garg

Department of Neurology

King George's Medical University

Lucknow, India: 226003

Mobile: +91 9335901790

Email: garg50@yahoo.com

Conflict of Interest All authors have no conflict of interest to report.

Background

Data related to psychiatric manifestations in SSPE is currently available only in form of isolated case reports. In this systematic review, we evaluated the spectrum of psychiatric manifestations and their impact on the course and outcome of SSPE.

Methods

Data were obtained from four databases (PubMed, Embase, Scopus, and Google Scholar), with the most recent search conducted on 27/03/2023. The PRISMA guidelines were followed, and the PROSPERO registration number for the protocol is CRD42023408227. SSPE was diagnosed using Dyken's criteria. Extracted data were recorded in an Excel spreadsheet. To evaluate the quality of the data, the Joanna Briggs Institute Critical Appraisal tool was employed.

Results

Our search resulted in 30 published reports of 32 patients. The mean age was 17.9 years. Schizophrenia, catatonia, and poorly characterized psychotic illnesses were the three most common psychiatric presentations (60%) in SSPE cases. Mania or depression was reported among 23% (7/32) cases. In 10% of cases, the initial clinical presentation of SSPE was considered functional/ hysterical. In approximately 81% (26/32) cases, the course of SSPE was rapidly progressive (either acute fulminant or

subacute). Treatment with antipsychotic drugs had poor or no response. Out of 17 patients who received antipsychotic drugs 6 patients noted severe extrapyramidal adverse effects, that further deteriorated the clinical condition of the patients.

Conclusion

Several patients with SSPE inadvertently end up in psychiatric care due to some psychiatric manifestation. Early psychiatric disorders in SSPE are often subtle and diagnosis of SSPE is easily missed.

Keywords:

Introduction

Subacute sclerosing panencephalitis (SSPE) is a relentlessly progressive brain disorder caused by the defective measles virus.

SSPE is common in measles-endemic areas. SSPE usually presents with progressive cognitive deterioration and myoclonus.

Children between 8 and 12 years of age are more frequently affected. SSPE is invariably fatal within 1–3 years from the onset. In an acute-fulminant variant of SSPE, the patient either dies or becomes akinetic mute within 6 months of disease onset.

Electroencephalography (EEG) reveals periodic discharges. Brain imaging reveals periventricular T2/ FLAIR white matter abnormalities. The advanced stage of SSPE is characterized by marked brain atrophy. A definitive diagnosis needs the demonstration of elevated measles antibody titers in the cerebrospinal fluid (CSF).^{1,2} Infrequently, pure psychiatric manifestations (like mania, psychosis, catatonia, and malingering) have also been reported in many SSPE patients. In this systematic review, we evaluated the spectrum of psychiatric manifestations of SSPE.

Material and methods

Protocol registration

We conducted a thorough analysis of published case reports and case series of SSPE patients, who either had psychiatric manifestations at the time of diagnosis or who later developed psychiatric manifestations. We used the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards for our systematic review. The protocol was made pre-registered in PROSPERO (CRD42023408227).³

Literature search

A literature search was done in the databases of PubMed, Scopus, Embase, and Google Scholar. In Google Scholar database, first 50 pages were screened for relevant articles. No language restrictions were imposed, while databases are searched. Articles, other than in English language were translated into English with the help of “A Google translator”.

The following search items were used in our search strategy: (((((((((((((PSYCHIATRIC) OR (Neuropsychiatric)) OR (Schizophrenia)) OR (Mania)) OR (Psychosis)) OR (Depression)) OR (Catatonia)) OR (Attention deficits)) OR (Anxiety)) OR (Panic attacks)) OR (Sleep disorders)) OR (Nightmares)) OR (Parasomnias)) AND (SSPE). The date of the last search was 27/03/2023.

Exclusion criteria

The articles that were omitted, included editorials, comments on previously published cases, and review articles. Conference abstracts were also not taken into account.

Data extraction

The study was conducted in two stages. Titles and abstracts were assessed by two independent reviewers in the initial phase (RK and IR). The full texts of the chosen papers were then examined by an additional set of two reviewers to determine their eligibility following the inclusion criteria (RK and IR). A third author was brought in to settle any differences between the two authors (AJ).

Dyken's criteria were used to identify cases with a confirmed diagnosis of SSPE (Table-1).⁴ Studies were considered if they fulfilled the following criteria: (1) they were case reports or case series; (2) they described cases of psychiatric manifestations in a case of SSPE; (3) cohort studies were included only if, individual patient data were available; and (4) they comprehensively described the psychiatric manifestations in confirmed SSPE cases.

Quality of studies

The critical appraisal checklist for case reports and case series given by the Joanna Briggs Institute (JBI) was used to assess the quality of published case reports.

The critical appraisal tool we used was an 8-item scale including the patient's demographic characteristics, clinical details, details of laboratory workup, the treatment administered, the follow-up clinical condition, adverse events, and the main takeaways from the case reports. Each of these criteria was used to evaluate every case. "Yes" or "No" was indicated for each point.⁵ Two independent

reviewers (SKK and RU) assessed the quality of the included cases, and any disagreements between them were resolved by mutual agreement, If still there was a dispute, it was resolved via discussion with a third reviewer (AJ).

Data analysis

Each patient's demographic information, history of measles infection or vaccination in infancy, length of illness, type of psychiatric manifestations, workup procedures, results of neuroimaging, and course and outcome were all noted. Four reviewers (RK, IR, HSM, and RU) completed all of them; in the event of a disagreement, assistance from a fifth reviewer was sought (AJ). To manage duplicate records, the web tool EndNote 20 (Clarivate Analytics) was employed. Two reviewers independently completed this process once more (SKK and AJ). Any problems were rectified with the assistance of another reviewer. A PRISMA flow chart was used to present the number of records that were retrieved and evaluated at each stage. PRISMA flow chart was prepared with the help of EndNote 20 (Clarivate Analytics). (Figure-1)

We used Microsoft Excel software, for data analysis. The necessary data was taken out and put together in an Excel document. The information we compiled included the first author, the nation of the report, the demographics of the patients, the status of childhood measles vaccination, childhood measles infection, length of illness, types of psychiatric manifestations, other clinical presentations, specifics of the reported diagnostic workup, neuroimaging, and the outcome. We focussed on the descriptive and

qualitative aspects of the data. Frequencies and percentages were employed to represent the categorical variables. Means, medians, or ranges were employed for reporting continuous variables.

Results

Our search resulted in 30 reports with information on 32 patients. (Table-2)⁶⁻³⁵ We compiled our data as per PRISMA standards. (Supplementary file-1- PRISMA checklist) Figure-1 shows the PRISMA flowchart for our systematic review. Table-3 summarises the demographic, clinical, neuroimaging, and brain/retina biopsy information of SSPE cases with psychiatric manifestations.

A supplemental Word file contains the critical appraisal report of each included case, according to the Joanna Briggs Institute (JBI) checklist. (Supplementary file -2). In An 8-item scale, the majority of cases (26/32) complied with all the points. Only 6 cases faltered on the point “post-intervention clinical condition”.

The mean age of SSPE patients was 17.9 years (median 15 years and range 2-62 years). Men outnumbered the females (21: 11). Majority (94%) of SSPE patients with psychiatric presentations either did not have childhood measles vaccination, or a reliable vaccination history was not retrievable. In one-third of instances, childhood measles infection was reported by relatives. The

majority of reports (73.3%) on SSPE patients with psychiatric presentations were from Turkey and India. After the year 2005, all such reports were excluded from these two countries only. (Table-3)

Schizophrenia, catatonia, and poorly characterized psychotic illnesses were the three most common psychiatric presentations (60%) in SSPE cases. Affective disorders, mania, and depression were reported among 23% (7/32) cases. In 10% of cases, the initial clinical presentation of SSPE was considered functional/ hysterical. In approximately 81% (26/32) cases the course of SSPE was rapidly progressive (either acute fulminant or subacute). (Table-3)

Neuroimaging abnormalities were detected in 63% (10/16) of patients, periventricular T2/FLAIR MR hyperintensities were the most frequently noted abnormalities. Brain biopsy findings were noted in 3 patients. Focal demyelination with gliosis, inflammatory cell infiltration, and the presence of inclusion bodies in neurons and oligodendroglia were dominant histopathological findings. (Table-3)

Treatment with antipsychotic drugs had poor or no response. Out of 17 patients who received antipsychotic drugs 6 patients noted severe extrapyramidal adverse effects, that further deteriorated the clinical condition of the patients. (Table-3)

Discussion

In this systematic review, we noted that many patients with SSPE were mistakenly referred to psychiatric care because of their psychiatric presentations. These patients frequently received diagnoses of affective disorders, including mania and depression, as well as psychotic diseases like schizophrenia, catatonia, and poorly defined psychotic illnesses. Treatment with antipsychotic drugs often failed, and severe extrapyramidal adverse effects were common. In the early stages, many children were misdiagnosed as malingering or hysterical.

Our review found that schizophrenia was the most common psychiatric diagnosis for many cases of SSPE. Schizophrenia is a mental disorder characterized by delusions, hallucinations, disorganized thinking, and other symptoms. Anti-N-methyl-d-aspartate (NMDA) receptor encephalitis is another brain disorder that can cause similar symptoms. It is often misdiagnosed as a psychiatric disorder, just as SSPE was in our review. NMDA receptor encephalitis is characterized by psychotic and affective symptoms, catatonic signs, and mental decline. It is also often associated with seizures, abnormal movements, and a fluctuating course. Fulminant SSPE can mimic NMDA receptor encephalitis, making it difficult to distinguish between the two conditions..³⁶⁻³⁸

The pathophysiology of underlying schizophrenia in SSPE is difficult to elucidate. The psychotic symptoms may result from the progressive destruction of brain tissue caused by chronic measles virus infection. One report indicated that individuals with persistent schizophrenia had significantly higher blood antimeasles antibody titers than those without a history of a psychiatric disorder.³⁹ Many studies have shown that schizophrenia is associated with lower brain volume particularly of gray matter and

cortical thickness, increasing gray matter loss, and abnormal gyral patterns.⁴⁰ Research has shown that there are structural changes in the brains of individuals with schizophrenia, and similar changes have been observed in the brains of individuals with SSPE. These changes include a reduction in brain volume, particularly in the frontal lobes, temporal lobes, and hippocampus, which are regions of the brain involved in cognitive and emotional processing. In patients with schizophrenia, neuropathological examinations and brain imaging studies suggest a variety of abnormalities in many brain regions, including the cerebral cortex, hippocampus, thalamus, and amygdala.⁴¹ Extrapyramidal reactions following treatment with antipsychotic medications are common and frequently lead to rapid deterioration. (Figure-2)

Catatonia is another frequent psychiatric manifestation in patients with SSPE. The pathogenesis of catatonia in SSPE is also not fully understood. Catatonia is believed to result from dysfunction of the frontostriatal network in the brain, which regulates motor and behavioral functions. The SSPE virus also targets the basal ganglia, which are a part of the frontostriatal circuitry. Damage to the basal ganglia can disrupt the normal functioning of this circuitry, leading to motor and behavioral abnormalities characteristic of catatonia. The measles virus targets the limbic system, which is responsible for emotional regulation. Damage to the limbic system may lead to dysfunction of the neural circuits involved in mood regulation, leading to depression. In addition to direct damage to brain tissue, alterations in neurotransmitter and immune system function are possible mechanisms involved in the pathogenesis of depression in SSPE.⁴²⁻⁴⁴

Many times, particularly in the early stages of the disease, SSPE is inadvertently considered "malingering". "Malingering" refers to the intentional feigning or exaggeration of symptoms for external gain, such as to avoid school work, or to gain attention or sympathy.^{45,46}

In conclusion, many patients with SSPE inadvertently end up in psychiatric care due to their psychiatric symptoms. Early psychiatric manifestations in SSPE are often subtle and the diagnosis of SSPE is easily missed. We suggest that if there is no satisfactory response to antipsychotic drugs or if there are early extrapyramidal reactions leading to further deterioration, the possibility of SSPE should be considered.

Declarations

Financial or non-financial support for the review= None

Competing interests of review authors= None to declare

References

1. Nair SS, Vysakha KV, Menon RN, Sundaram S. Adult-onset subacute sclerosing panencephalitis. Pract Neurol. 2021;practneurol-2020-002880.

2. Garg RK, Mahadevan A, Malhotra HS, Rizvi I, Kumar N, Uniyal R. Subacute sclerosing panencephalitis. Rev Med Virol. 2019;29(5):e2058.
3. Garg RK, Rizvi I, Malhotra HS, Pandey S, Kar SK, Uniyal R, Jain A. The spectrum of neuropsychiatric manifestations in subacute sclerosing panencephalitis: a systematic review of published case reports and case series. PROSPERO 2023 CRD42023408227 Available from: https://www.crd.york.ac.uk/prospERO/display_record.php?ID=CRD42023408227
4. Joanna Briggs Institute 2017 Critical Appraisal Checklist for Case Reports. https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Case_Reports2017_0.pdf. Assessed on 1 April, 2023.
5. Dyken PR. Subacute sclerosing panencephalitis. Current status. Neurol Clin. 1985;3(1):179-96.
6. Koehler K, Jakumeit U. Subacute sclerosing panencephalitis presenting as Leonhard's speech-prompt catatonia. Br J Psychiatry. 1976;129:29-31.

7. Moodie JW, Philcox D, Naudé WD, Lipper S, Kipps A. Atypical presentation of subacute sclerosing panencephalitis in 3 patients. S Afr Med J. 1980;58(24):968-71.
8. Caplan R, Tanguay PE, Szekely AG. Subacute sclerosing panencephalitis presenting as childhood psychosis. J Am Acad Child Adolesc Psychiatry. 1987;26(3):440-3.
9. Salib EA. Subacute sclerosing panencephalitis (SSPE) presenting at the age of 21 as a schizophrenia-like state with bizarre dysmorphophobic features. Br J Psychiatry. 1988;152:709-10.
10. Duncalf CM, Kent JN, Harbord M, Hicks EP. Subacute sclerosing panencephalitis presenting as schizophreniform psychosis. Br J Psychiatry. 1989;155:557-9.
11. Mattinson PJ. Suspected SSPE--a delayed psychiatric presentation. Br J Psychiatry. 1989;154:116-8.

12. Forrest G, Stores G. Subacute sclerosing panencephalitis presenting with psychosis and possible sexual abuse. *Eur Child Adolesc Psychiatry*. 1996;5(2):110-3.
13. Jähnel M. Paranoid-halluzinatorische Psychose als Erstmanifestation einer subakuten sklerosierenden Panenzephalitis (SSPE) bei einem 19-jährigen Mann. *Psychiatrische Praxis*. 2003;30(S 2):70-2.
14. Datta SS, Jacob R, Kumar S, Jeyabalan S. A case of subacute sclerosing panencephalitis presenting as depression. *Acta Neuropsychiatr*. 2006;18(1):55-7.
15. Kayal M, Varghese ST, Balhara YP. Psychiatric manifestation of SSPE. *J Neuropsychiatry Clin Neurosci*. 2006;18(4):560.
16. Theethira TG, Ravat SH, Shah PU, Oak PJ, Godge YR, Chengappa KR. Subacute sclerosing panencephalitis presenting as schizophreniform disorder. *Acta Neuropsychiatrica*. 2009;21(1):45-7.
17. Baran Z, Hanağasi H, Uçok A. An unusual late presentation of subacute sclerosing panencephalitis with psychotic symptoms. *J Neuropsychiatry Clin Neurosci*. 2010;22(1):123.E13.

18. Aggarwal A, Jain M, Jiloha R. Catatonia as the initial presenting feature of subacute sclerosing panencephalitis. *J Neuropsychiatry Clin Neurosci.* 2011;23(1):E29-31.
19. Aggarwal A, Khandelwal A, Jain M, Jiloha RC. Subacute sclerosing panencephalitis presenting as mania. *Ann Indian Acad Neurol.* 2011;14(2):120-1.
20. Altunkaynak Y, Yıldırım Z, Ertem DH, Dirican AC, Baybaş S. Late Onset Subacute Sclerosing Panencephalitis: Presenting Psychosis. *J Clin Anal Med* 2013;4(suppl2): 220-2.
21. Dayal P, Balhara YP. Catatonia as presenting clinical feature of subacute sclerosing panencephalitis. *J Pediatr Neurosci.* 2014;9(1):57-9.
22. Kartal A, Kurt AN, Gürkaş E, Aydın K, Serdaroğlu A. Subacute sclerosing panencephalitis presenting as schizophrenia with an alpha coma pattern in a child. *J Child Neurol.* 2014;29(10):NP111-3.

23. Erdogan S, Yilmaz R, Sorgun MH, Aydin N. Mania as a presenting clinical feature of subacute sclerosing panencephalitis. *Acta Neurol Belg*. 2015;115(4):803-5.
24. Manoj S, Mukherjee A, Kumar KV. Subacute sclerosing panencephalitis presenting with hypersexual behavior. *Indian J Psychiatry*. 2015;57(3):321-2.
25. Parmar A, Ranjan R, Sagar R. Subacute Sclerosing Panencephalitis Presenting with Isolated Positive Psychotic and Catatonic Symptoms. *Indian J Psychol Med*. 2017;39(4):534-536.
26. Tak ZA, Celik M, Kalenderoğlu A, Sağlam S, Ekmekci B, Altun Y. A Case of Sub-Acute Sclerosing Panencephalitis Presenting with Nonspecific Psychiatric Symptoms. *Turk Psikiyatri Dergisi*. 2017;28(3):221.
27. Ahmad J, Kar SK, Uniyal R. Acute and transient psychotic disorder as a rare early manifestation of late-onset sub-acute sclerosing panencephalitis. *Neurology, Psychiatry and Brain Research*. 2018;30:35-8.

28. Bhat BA, Dar SA, Hussain A. Sub-Acute Sclerosing Panencephalitis Presenting as Anti-Depressant Induced Childhood Mania. J Psychiatry. 2018;21:1000452.
29. Reddy B, Das S, Guruprasad S. Primary Psychiatric Manifestations of Subacute Sclerosing Panencephalitis: A Case Report and Literature Review. Psychosomatics. 2018;59(4):408-412.
30. Gokoglu A, Gozdas HT. Adult-Onset Subacute Sclerosing Panencephalitis Presented with Neuropsychiatric Symptoms. J Coll Physicians Surg Pak. 2019;29(6):S29-S30.
31. Arora S, Jolly AJ, Suhas S, Arasappa R, Kamble N, Pal PK, Varambally S. Subacute Sclerosing Panencephalitis Masquerading as Schizophrenia: An Example of Diagnostic Overshadowing in Neuropsychiatry. Prim Care Companion CNS Disord. 2022;24(3):21cr02997.
32. Sutar R, Rai NK. Revisiting periodic catatonia in a case of SSPE and response to intrathecal interferon: A case report. Asian J Psychiatr. 2020;51:101996.

33. Chakraborty K, Chatterjee M, Bhattacharyya R, Neogi R. Case of Subacute Sclerosing Pan-Encephalitis (SSPE) presenting as catatonic schizophrenia. *Journal of Indian Association for Child and Adolescent Mental Health*. 2021;17(2):204-9.
34. Kaur G. Sub-Acute Sclerosing Panencephalitis Manifesting As Psychiatric Illness: A Case Report. *Sch J Med Case Rep*. 2021;10:938-41.
35. Jain P, Sehgal A, Purohit K, Sajjan C. SSPE presented as catatonia: case report. *World Journal of Pharmaceutical Research*. 2022;11:1723-1726.
36. Espinola-Nadurille M, Restrepo-Martínez M, Bayliss L, Flores-Montes E, Rivas-Alonso V, Vargas-Cañas S, Hernández L, Martínez-Juarez I, Gonzalez-Aguilar A, Solis-Vivanco R, Fricchione GL, Flores-Rivera J, Ramirez-Bermudez J. Neuropsychiatric phenotypes of anti-NMDAR encephalitis: a prospective study. *Psychol Med*. 2022 May 10:1-9.
37. Hinotsu K, Miyaji C, Yada Y, Kawai H, Sakamoto S, Okahisa Y, Tsutsui K, Kanbayashi T, Tanaka K, Takao S, Kishi Y, Takaki M, Yamada N. The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms. *Schizophr Res*. 2022;248:292-299.

38. Garg RK, Kumar N, Rizvi I, Pandey S, Malhotra HS, Uniyal R. Fulminant Subacute Sclerosing Panencephalitis Mimicking Autoimmune Encephalitis. *Pediatr Infect Dis J*. 2019;38(3):e64.
39. Dickerson F, Stallings C, Origoni A, Copp C, Khushalani S, Yolken R. Antibodies to measles in individuals with recent onset psychosis. *Schizophr Res*. 2010;119(1-3):89-94.
40. Howes OD, Cummings C, Chapman GE, Shatalina E. Neuroimaging in schizophrenia: an overview of findings and their implications for synaptic changes. *Neuropsychopharmacology*. 2023;48(1):151-167.
41. Insel TR. Rethinking schizophrenia. *Nature*. 2010;468(7321):187-93.
42. Tandra HV, Roy PS, Sharma R, Bhatia V, Saini AG. Subacute Sclerosing Panencephalitis Presenting as Chorea and Basal Ganglia Hyperintensities. *Neurohospitalist*. 2019;9(1):26-29.

43. Lebon S, Maeder P, Maeder-Ingvar M, Poloni C, Mayor-Dubois C, Roulet-Perez E, Jeannet PY. An initial MRI picture of limbic encephalitis in subacute sclerosing panencephalitis. *Eur J Paediatr Neurol*. 2011;15(6):544-6.
44. Sawaishi Y, Yano T, Watanabe Y, Takada G. Migratory basal ganglia lesions in subacute sclerosing panencephalitis (SSPE): clinical implications of axonal spread. *J Neurol Sci*. 1999;168(2):137-40.
45. Prashanth LK, Taly AB, Sinha S, Ravi V. Subacute sclerosing panencephalitis (SSPE): an insight into the diagnostic errors from a tertiary care university hospital. *J Child Neurol*. 2007;22(6):683-8.
46. Sutton T. Psychological testing: art, science and mysticism. *PRECEDENT* 2010;99:39-43.

**Table-1: Dyken's diagnostic criteria of subacute sclerosing panencephalitis (SSPE)
(Any three of 4 components)**

Clinical

Progressive deterioration in mental function
periodic axial myoclonus

Electroencephalography

Periodic discharges

Cerebrospinal fluid

Serum globulin concentrations > 20% of the total cerebrospinal fluid protein
Elevated cerebrospinal fluid measles antibody levels

Brain biopsy

Histopathology suggestive of panencephalitis
Inclusion bodies in neurons
Presence of measles virus or its genetic components in the brain

Table-2: Epidemiological, clinical features, neuroimaging findings, histopathological features and outcome of patients of SSPE with psychiatric manifestations

Reference	Country	Age/sex	Measles vaccination	Childhood measles	Duration of illness before presentation	Psychiatric manifestation	Clinical features	Neuroimaging	Brain biopsy	Course of illness	Treatment and its response	Outcome
Koehler and Jakumeit 1976	Germany	20/F Pregnant	NA	NA	2 weeks	Hysterical blindness Leonhard's speech-prompt catatonia	Vision loss Denial of vision loss She was cheerful despite vision loss Vision loss was interpreted as hysterical "la belle indifference" Auditory hallucinations Generalized catatonic rigidity Soon progressed to encephalopathy	NA	NA	Acute fulminant	NA	Delivered a normal baby Became akinetic mute in few months
Moodie 1980	South Africa	16/F	NA	NA	2 days	Schizophrenia	Paranoid behavior and auditory hallucinations	NA	Perivascular infiltration Increase in microglial cells Dead and	Acute fulminant	NA	Died 7 days later

									'dying' neurons within the cortex excessive subpial gliosis Intranuclear inclusions in neurons and oligodendroglia No measles antigen could be demonstrated			
Caplan et al 1987	USA	9/F	NA	NA	6 months	Childhood schizophrenia	Psychomotor agitation Insomnia delusions Declining scholastic performance Speech incoherence, echolalia, Auditory hallucinations Myoclonus	NA	NA	Chronic	Thioridazine Extrapyramidal side effects Later Phenothiazine and chlorpromazine	Died 2 years after
		11/M	NA	Measles at age 3 years	Sudden	Acute schizophrenia	A behavioral disorder Hyperactivity, aggressive behavior Inappropriate laughing. Suicidal	NA	NA	Acute fulminant	chlorpromazine	Akinetic mute within 4 weeks Died 1 year later

							ideation Neologisms, perseveration, and echolalia Thought disorders Social withdrawal. Myoclonus					
Salib 1988	United kingdom	21/M	NA	NA	8 months	Schizophrenia-like state with bizarre dysmorphophobia	Withdrawn and apathetic Preoccupied with the shape of various body parts Clumsy anxious, restless, and agitated	CT= normal	NA	Subacute	Treated in psychiatry unit.	He died 8 months later
Duncalf et al 1989	Australia	21/F	NA	NA	2 months	Schizophrenia	Delusions Fearful and perplexed with echolalia. Lately withdrawn, agitated and had echolalia	NA	Generalized grey matter atrophy Diffuse demyelination Inclusion bodies in neurons	Acute fulminant	Fluphenazine Psychotic symptoms improved But had extrapyramidal side effects	Died within 6 months
Mattinson 1989	United Kingdom	44/F	NA	Measles at 5 years	Sudden	Functional psychiatric disorders	Poor recent memory Emotional lability Social disinhibition Dysarthria and gait	NA	Focal demyelination with gliosis Inflammatory cell infiltration Virus inclusion	Acute fulminant	NA	Died 9 weeks later

							abnormality		bodies Measles virus was not demonstrated.			
Forrest and Stores 1996	United Kingdom	9/F	NA	Measles at the age of 2	4 months	Psychosis and possible sexual abuse	Nightmares seeing 'aliens' in a dream Alleged attack by a bald man Disorientated and uncooperative Myoclonus and progressive encephalopathy	NA	NA	Acute fulminant	NA	Died after 3 months
Jähnel 2003	Germany	19/M	NA	NA	2 months	Schizophrenia	Auditory and visual hallucinations Lack of interest Decreased drive Seizures and Myoclonus	T2/FLAIR hyperintensity in pons	NA	Acute fulminant	Flupentixol	Died within 2 months
Datta et al 2006	India	24/M	NA	NA	5 months	Depression Moderate depression with somatic symptoms according to ICD-10 classification	Feeling sad Loss of interest Increased fatigue and lethargy Multiple somatic complaints and insomnia	CT=normal	NA	Acute fulminant	Sertraline	Died within 2 months

Kayal et al 2006	India	13/M	No vaccination	had measles at the age of 5	2 months	Major depression	2 months later, Myoclonus and encephalopathy Quiet and withdrawn Confined to home Lost his cheerfulness Inappropriate crying and laughter Difficulty in walking Myoclonus and encephalopathy	Normal	NA	Acute fulminant	Fluoxetine	Rapidly became bed ridden
Theethira et al 2009	India	15/M	Not received	measles at 8 months of age	Several months	First episode schizophreniform disorder (International Classification of Diseases (ICD) F20.8)	Paranoid and self-referential delusions Later Recurrent falls Myoclonus and encephalopathy	NA	NA	NA	A first-generation antipsychotic drug	Lost to follow up
Baran et al 2010	Turkey	31/M	NA	Measles at 9 years	1 year	Schizophrenia Catatonia	Delusions and depressive mood Catatonia Cognitive decline Akinetic	Normal	NA	Subacute	Olanzapine Extrapyramidal side effects ECT	NA

							mutism					
Aggarwal et al 2011	India	13/M	NA	NA	5 months	Catatonia The Bush Catatonia Rating Scale scored 7.	Withdrawn behavior and decreased interaction, mutism. Prolonged standing, clenching of teeth, violent behaviour Poor scholastic performance Akinetic mutism	T2/FLAIR hyperintensit y foci in periventricula r region	NA	Acute fulminant	Lorazepam No improvement	Lost to follow up.
Aggarwal et al 2011	India	14/M	NA	NA	1 month	Mania	Behavioural changes Became talkative, irritable and angry Frequent bathing and reduced sleep Increased psychomotor activity Myoclonus and encephalopat hy	T2/FLAIR hyperintensit y foci in periventricula r region mainly parieto- occipital region	NA	Acute fulminant	Olanzapine Unduly sedated and urinary incontinence	Lost to follow up.
Altunkaynak et al 2013	Turkey	19/F	NA	NA	1 year	Atypical psychotic disorder First episode schizophrenia Admitted in psychiatry	Behavioral changes Later, myoclonus and encephalopat hy	NA	NA	Subacute	Antipsychotic treatment	Died within 1 year

Dayal and Balhara 2014	India	14/M	NA	NA	6 months	Catatonia	Reduced interaction Catatonic posture and clenching of teeth Make poor eye contact and would resist attempts at moving him	NA	NA	Acute fulminant	Lorazepam Reduction in BFCRS score to 4.	4 months later developed diffuse encephalopathy Lost to follow up.
Kartal et al 2014	Turkey	14/F	NA	NA	3 months	Schizophrenia	Insomnia Visual and auditory hallucinations Behavioural changes and Mental decline Agitation	Normal	NA	Acute fulminant	Olanzapine No response	NA
Erdogan et al 2015	Turkey	20/M	NA	NA	6 months	Mania	Manic episode abnormal repetitive movements in his hands and legs and irritability. irritable and angry worked for long hours and slept very little He spent his money intemperately and bought himself new clothes every	T2/FLAIR hyperintensity In splenium of corpus callosum	NA	Chronic course	Olanzapine	Died 2 years

							day. full of energy and never felt tired.					
Manoj et al 2015	India	23/F	No	Present	1 year	Hypersexual syndrome	Behavioral abnormalities	T2/FLAIR hyperintensity	NA	Subacute	Risperidone	Died after 1 year
		27/M	No	Present	2 year	Hypersexual syndrome	Behavioral abnormalities	T2/FLAIR hyperintensity		Chronic progressive	Risperidone	Akinetic mute
Parmar et al 2017	India	15/M	NA	NA	5 months	Schizophrenia catatonia	Behavioral changes Insomnia Delusions and hallucination Smiling and muttering to self Incontinence Repeated motor acts (clapping continuously) Catatonic posturing	T2/FLAIR hyperintensity foci in periventricular region	NA	Acute fulminant	Risperidone	NA
Tak et al 2017	Turkey	14/M	Fully vaccinated	measles infection at the age of 4 months	9 months	Nonspecific symptoms led to psychiatric consultation	Poor scholastic performance Decreased communication Difficulty in finding appropriate words Lately, myoclonus	MRI=normal	NA	Subacute	NA	Discharged on mechanical ventilation

							and diffuse encephalopathy.					
Ahmad et al 2018	India	26/M	NA	NA	2 months	Acute and transient psychotic disorder	Withdrawn behavior, muttering to self and inappropriate smiling, reduced self-care Impaired sleep and disorganized behavior Myoclonus and encephalopathy	T2/FLAIR hyperintensity foci in periventricular region mainly frontal-parietal region	NA	Acute fulminant	Olanzapine Severe extrapyramidal side effects (parkinsonian symptoms)	Improvement in his psychotic symptoms but he developed severe extrapyramidal side effects
Bhat et al 2018	India	8/M	NA	NA	7 days	Childhood depression with antidepressant induced mania	Change in behaviour Excessive talking, overfamiliar behaviour, decreased sleep, spitting, excessive playing and hyperactivity	NA	NA	Acute fulminant course	Fluoxetine	No improvement after 2 weeks
Reddy et al 2018	India	17/M	NA	NA	1 year	Moderate depression	Poor scholastic performance Crying spells, and irritability Sudden drop of objects from hands 4 months later, Repeated fall myoclonus	T2/FLAIR hyperintensity foci in periventricular region	NA	Subacute	Psychotherapy and fluoxetine	NA

							and encephalopathy					
Gökoglu Gözdaş 2019	Turkey	62/F	NA	NA	3 years	Depression initially	Meaningless speech Memory loss Gait disorder	T2/FLAIR hyperintensity foci in periventricular region	NA	Chronic progressive	Amantadine	clinical and radiological improvement.
Arora et al 2022	India	19/M	Incomplete	Exanthematous febrile illness at 7 years of age	3 years	Schizophrenia	Apathy, personality change Auditory and tactile hallucinations Severe cognitive decline Myoclonus	NA	NA	Chronic progressive	Aripiprazole	No further deterioration after 6 months
Sutar and Rai 2020	India	13/M	NA	NA	8 months	Periodic catatonia Busch Francis Catatonia rating scale (BFCRS) score was 8	acute abnormalities in sleep cycle Episodes of slowness and excitement Poor scholastic performance Alternating episodes of slowness and excitation Recurrent falls Mutism, and psychomotor slowing Intermittently, period of psychomotor agitation and	NA	NA	Subacute	Lorazepam Intrathecal interferon α2b	His intake oral and sleep improved.

							irritability 4 months later, myoclonus and encephalopathy					
Chakraborty et al 2021	India	15/M	NA	NA	6 months	Catatonic schizophrenia	Smiling and muttering to self Catatonia Episodes of aggression Attempts to run out of home Poor self-care Myoclonus	NA	NA	Acute fulminant	Amisulpride and oral lorazepam olanzapine acute extrapyramidal side effects	Alive after more than 3 years of follow up.
Kaur et al 2021	India	17/F	NA	NA	1 year	Schizophrenia	Behavioral changes Social withdrawal Irrelevant talk and laughter	NA	NA	Acute fulminant	Risperidone No response	Became akinetic mute within few weeks
Jain et al 2022	India	18/M	NA	NA	4 months	Functional neurological disorder Later Catatonia	Behavioral changes Unresponsive episodes Soon became mute and had catatonic posture Encephalopathy and	NA	NA	Acute fulminant	Levetiracetam Lorazepam	NA

							myoclonus					
--	--	--	--	--	--	--	-----------	--	--	--	--	--

Table-3: Summary of epidemiological, clinical features, neuroimaging findings, histopathological features and outcome of patients of SSPE with psychiatric manifestations (n=32)

Age (in years)	Mean= 19.4 Median=17
----------------	-------------------------

	Mode= 14 Range= 8-62 Interquartile Range= 7
Sex	Female= 11 (34.3%) Male= 21 (65.6%)
Measles vaccination	Yes= 2 (6.2%) No/NA= 30 (93.7%)
Childhood measles	Yes= 10 (31.2%) No or NA= 22 (68.8%)
Geographical areas of reported cases (total 30 reports)	India= 16 (53.3%) Europe, except Turkey = 5 (16.7%) Turkey= 6 (20%) USA = 1 (3.3%) Australia= 1 (3.3%) Africa= 1 (3.3%)
course of the disease	Acute fulminant= 19 (59.3%) Subacute= 7(21.9%) Chronic =5 (16.6%) NA=1 (3.1%)
Dominant psychiatric illness	Catatonia=3 (9.4%) Depression= 5 (16.6%) Functional neurological disorder/ Hysterical= 3 (9.4%) Hypersexuality=2 (6.3%) Mania= 2(6.3%) Schizophrenia/ ill-defined psychotic disorders=16 (50%) Non-specific= 1(3.1%)
Neuroimaging	NA= 16 (50%) Normal= 6 (18.8%) T2/FLAIR periventricular hyperintensity= 8 (25%) Pontine hyperintensity= 1 (3.1%)

	Splenium of the corpus callosum hyperintensity =1 (3.1%)
Brain biopsy	NA=29 (90.6%) Done=3 (9.4%)

NA= not available; FLAIR= Fluid attenuated inversion recovery

Legends

Figure-1

PRISMA flow diagram of the study shows the process of article selection for systematic review.

Figure-2

Flow diagram depicts progression of course of disease in SSPE patients with psychiatric manifestations.

Identification of studies via databases and registers

Identification

Records identified from
Databases= 453

PubMed= 143
Scopus= 56
Embase= 192
Google Scholar= 62

Records removed *before
screening*:

Duplicate records
removed= 148

Screening

Records screened= 305

Records excluded after review
of title and abstract= 238

Reports sought for full text
retrieval= 67

Reports not retrieved= 8

Reports assessed for
eligibility= 59

Reports excluded= 29

Studies with no individual
patient data = 2
Conference abstract only= 10
Book chapter/ review article= 4
Psychiatric manifestations not
reported= 6
Patients were not of SSPE= 5
Other irrelevant articles = 2

Included

Reports of included in the
review = 30

Total cases reported= 32

